Healthcare Industry News:  fractional skin resurfacing 

Devices Dermatology Product Launch

 News Release - June 14, 2013

Lumenis Launches New Fractional Non-Ablative Laser Module, the ResurFX(TM), at the 22nd Annual Meeting of the German Dermatologic Laser Society in Potsdam

The M22 Is Now the Only Multi-Application System With a True Fractional Non-Ablative Module, Enabling Physicians to Successfully Treat a Broad Range of Skin Conditions

BERLIN--(Healthcare Sales & Marketing Network) - Lumenis Ltd., the world's largest medical laser company for ophthalmic, surgical and aesthetic applications, will launch ResurFX™ in Germany at the 22nd Annual Conference of the German Dermatologic Laser Society (DDL). ResurFX is Lumenis' new application for the M22™ platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing and treat some of the most common aesthetic skin conditions, including acne scars, surgical scars, periorbital wrinkles and stretch marks.

The M22 is the only multi-application platform that combines three gold-standard technologies covering more than 40 indications in one system: Intense Pulsed Light (IPL) with Optimal Pulse Technology™, Multi-spot Nd:YAG and now the ResurFX for a complete aesthetic workstation. ResurFX extends the already proven M22 capabilities and provides physicians with the only CoolScan™ enabled fractional non-ablative module with no disposables. The patent-pending CoolScan™ scanner delivers the 1565 nm fiber laser energy in a way that maximizes efficacy and reproducible results. CoolScan™ uses a proprietary algorithm that places each fractional spot in a controlled, non-sequential manner allowing the tissue to relax between pulses and protects it from overheating.

The M22 ResurFX module enables facial skin resurfacing, one of the fastest growing minimally invasive procedures in recent years. fractional skin resurfacing is also an effective way to treat striae, commonly known as stretch marks. Over 60% of women have stretch marks which appear often as result of pregnancy, weight gain and puberty.

"I have many patients that seek skin resurfacing solutions but who are not willing to accept the downtime of ablative CO2 treatments," said Dr. Matteo Tretti Clementoni, from LaserPlast clinic in Milan. "With the new ResurFX module I can now offer them an effective fractional non-ablative treatment with minimal downtime. The ResurFX module offers true freedom and flexibility as it is the only one that simultaneously allows choosing the density, energy, dimensions and the shape of the scan. The CoolScan scanner allows increasing the energy per single shot, hence increasing efficacy while not compromising on comfort and safety. CoolScan also allows increasing the density of spots per scan, allowing for single pass, faster treatments."

"The ResurFX module is a cost effective solution for physicians to treat the broadest range of common skin conditions," said Roy Ramati, Vice President & General Manager of the Aesthetic Strategic Business Unit at Lumenis. "It is the only fractional non-ablative module with the proprietary CoolScan algorithm to maximize efficacy and reproducible results. We now are able to offer dermatologists three gold-standard technologies in a single platform and plan to continue to deliver innovative solutions in the future."

Lumenis will have a range of educational events taking place at its booth through the congress.

On Friday, June 14th

At 14:00 Dr. Gerd Kautz, one of the most established German experts within IPL technology, will talk about the M22™ platform and the new ResurFX module.

Earlier, at 13:00 Dr. Klaus Hoffmann from the University of Bochum will share his experience with the Lumenis UltraPulse™.

In the evening, Prof. Alina Fratila, an internationally recognized speaker, will show a live blepharoplastic treatment with UltraPulse.

About Lumenis

Lumenis Ltd., the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for Aesthetic, Surgical and Ophthalmic applications, and has more than 900 employees worldwide. Lumenis holds approximately 250 patents, has over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavours to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning "Light of Life" highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please visit:

For more information about Lumenis and its products, please visit:

CoolScan™, Optimal Pulse Technology™, ResurFX™, Lumenis® and the Lumenis logo are trademarks or registered trademarks of Lumenis, Ltd.

Source: Lumenis

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.